STOCK TITAN

Jasper Therapeutics (JSPR) S-3 Filings

JSPR NASDAQ

Here are the S-3 shelf registrations from Jasper Therapeutics, Inc. (JSPR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.

Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) registered for resale up to 284,013,011 shares of common stock issuable upon conversion of 4,655,951 shares of PIPE preferred stock. Each preferred share converts into 61 common shares on the third business day after stockholder approval, subject to beneficial ownership limits. Jasper will receive no proceeds from selling stockholders’ sales; the selling stockholders receive the proceeds, while Jasper bears registration costs. Jasper says sales of substantial amounts could depress its share price and affect its ability to raise equity capital.

Jasper acquired Kira Pharmaceuticals on July 16, 2026, and a separate private placement closed on July 20, 2026, for approximately $132.0 million in gross proceeds. The company reported an accumulated deficit of $320.6 million as of June 30, 2026, and concluded substantial doubt exists about its ability to continue as a going concern within one year from filing its quarterly report for that period. Jasper said it is actively seeking additional capital and may delay, reduce or eliminate research and development programs if it cannot obtain adequate financing when needed or on acceptable terms.